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Abstract
Background: One of the most exciting and talked about new surgical techniques in breast cancer
surgery is the sentinel lymph node biopsy. It is an alternative procedure to standard axillary lymph
node dissection, which makes possible less invasive surgery and side effects for patients with early
breast cancer that wouldn't benefit further from axillary lymph node clearance. Sentinel lymph node
biopsy helps to accurately evaluate the status of the axilla and the extent of disease, but also
determines appropriate adjuvant treatment and long-term follow-up. However, like all surgical
procedures, the sentinel lymph node biopsy is not appropriate for each and every patient.
Methods: In this article we review the absolute and relative contraindications of the procedure in
respect to clinically positive axilla, neoadjuvant therapy, tumor size, multicentric and multifocal
disease, in situ carcinoma, pregnancy, age, body-mass index, allergies to dye and/or radio colloid
and prior breast and/or axillary surgery.
Results: Certain conditions involving host factors and tumor biologic characteristics may have a
negative impact on the success rate and accuracy of the procedure. The overall fraction of patients
unsuitable or with multiple risk factors that may compromise the success of the sentinel lymph
node biopsy, is very small. Nevertheless, these patients need to be successfully identified,
appropriately advised and cautioned, and so do the surgeons that perform the procedure.
Conclusion: When performed by an experienced multi-disciplinary team, the SLNB is a highly
effective and accurate alternative to standard level I and II axillary clearance in the vast majority of
patients with early breast cancer.
Background
The pathologic status of the axillary lymph nodes remains
the most important prognostic indicator for patients with
breast cancer and a major determinant of adjuvant treat-
ment. Sentinel lymph node biopsy (SLNB) has become a
widely accepted evaluation and staging procedure for the
axilla in patients with breast cancer, and this is mainly due
to the minimal morbidity and the high degree of histolog-
ical accuracy it provides. When performed by an experi-
enced multi-disciplinary team, the SLNB is a highly
effective and accurate alternative to standard level I and II
axillary clearance. To ensure and maintain the high accu-
racy and low false-negative rate of the SLNB procedure,
several selection criteria and relative contraindications for
Published: 29 January 2007
World Journal of Surgical Oncology 2007, 5:10 doi:10.1186/1477-7819-5-10
Received: 11 July 2006
Accepted: 29 January 2007
This article is available from: http://www.wjso.com/content/5/1/10
© 2007 Filippakis and Zografos; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.World Journal of Surgical Oncology 2007, 5:10 http://www.wjso.com/content/5/1/10
Page 2 of 11
(page number not for citation purposes)
the procedure have been reported, together with few
safety issues. These contraindications include host factors
such as disturbed lymphatics due to prior breast and axil-
lary biopsy and/or surgery, age, body-mass index, preg-
nancy, and tumor biologic characteristics such as tumor
size, multifocal or multicentric disease and histological
type (in situ carcinomas). Furthermore, safety issues like
radiation levels to patient (especially during pregnancy)
and medical stuff as well as storage and disposal of radio-
active waste, still remain debatable issues. Certain authors
suggest that when present, these factors may affect nega-
tively the accuracy of the SLNB, resulting in failure of the
procedure or higher than acceptable false negative results.
We review the literature in respect to each and every one
of those factors and discuss the impact they may have on
the degree of accuracy and efficacy of the procedure.
Absolute contraindications for SLNB
Clinically positive (N1) axilla
The absolute contraindications for the SLNB are quite
clear and straightforward. When there is clinically suspi-
cious axillary lymphadenopathy or when fine needle aspi-
ration cytology and/or core biopsy of palpable axillary
lymph nodes confirm tumor infiltration, the procedure is
contraindicated. According to the American Society of
Clinical Oncology Guideline Recommendations for Senti-
nel Lymph Node Biopsy in 2005 and the 2001 Proceed-
ings of the Consensus Conference on the Role of SLNB in
Carcinoma of the Breast in Philadelphia [1,2], patients
with clinically positive axilla (N1) are not candidates for
the procedure. It has been suggested that in such cases, the
path of the dye or the radio-colloid agent may be blocked
from tumor cells infiltrating the lymph vessels. This could
prevent the identification of the true sentinel node(s) and
result in failure of the procedure or false negative results.
Sentinel lymph node biopsy is best reserved for breast
cancer patients with clinically negative axillary nodes [3],
except perhaps in the setting of clinical trials. However, for
those patients with suspicious axillary findings, preopera-
tive ultrasound and fine needle aspiration (FNA) cytology
can provide further information on the status of the nodes
and help surgical planning. Approximately, 40% of
patients with positive axillary nodes can be diagnosed pre-
operatively with ultrasonography and FNA cytology alone
[4]. In node positive patients a standard level I and II axil-
lary clearance is indicated and SLNB is not performed. In
patients with clinically suspicious nodes and negative
FNA cytology, SLNB can be performed if bearing in mind
that any clinically suspicious palpable axillary nodes
encountered during the procedure should be excised and
examined, regardless of whether they take up dye or radio-
colloid, even if they are not the true sentinel node(s) [1,2].
Allergy to blue dye and radio-colloid
History of allergy to the radio-colloid and/or blue dye
should be considered contraindication to the use of that
specific agent. There has been observed no cross-reactivity
between these two agents. In the United States the most
commonly used agents are technetium sulphur colloid
and isosulfan blue dye, whereas in Europe technetium
labelled albumin and patent blue. Blue dyes used for lym-
phatic mapping in sentinel lymph node biopsy cause
intraoperative anaphylactic reactions in up to 2.7% of
patients [5,6]. These agents include patent blue, isosulfan
blue and methylene blue. The sodium salt of patent blue
is also called sulfan blue, food blue 3, patent blue VF, and
acid blue 1. Isosulfan blue is a structural isomer of patent
blue (not patent blue V) and is known under the trade
name lymphazurine. Patent blue V has a slightly different
chemical structure and can also be found under the name
patent blue violet, food blue 5, acid blue 3, and disulfine
blue. It is also known as E 131 and is still on the market
as a food colorant. However, because of the close struc-
tural relationship of these vital dyes, cross-reactivity may
indeed exist [5]. Methylene blue (anhydrous methylene
blue or methylene blue trihydrate), is only approved for
intravenous administration for the treatment of methe-
moglobinemia and hemolysis because it may cause necro-
sis on subcutaneous administration. Methylene blue is
structurally not related to isosulfan blue or patent blue V
and, therefore, cross-reactivity is not to be expected. How-
ever, according to certain authors, since methylene blue
has no sulfonic acid groups it does not bind to plasma
proteins and might not be taken up by lymph, diffusing
directly into blood capillaries [6]. For the detection of
hypersensitivity (mainly type I) to blue dyes, intracutane-
ous tests are valuable tools. In most cases, sensitization
exists without known previous exposure, and this may be
due to the widespread use of such dyes in objects of eve-
ryday life. Allergy to cosmetics containing blue dye consist
a relative contraindication in the use of the blue dye, but
previous allergic reactions to sulfa or sulphur do not pre-
dict reaction to the dye [1]. At least two deaths have been
described from anaphylactic reactions to the blue dye and
while adverse reactions in general are very rare (1–3%),
they can be extremely severe. Preoperative antiallergic
medication use does not prevent anaphylactic reactions
but greatly reduces their severity [7]. Patients with sulfa
allergies and prior exposure to lymphatic mapping do not
generally demonstrate an increased incidence of adverse
drug reactions [8].
Combined use of blue dye and radio-colloid is considered
to be a very effective technique and some authors suggest
an overall added value for the sentinel lymph node biopsy
[9,10], especially when young surgeons are just learning
how to perform the procedure. Whether both techniques
together are superior to either alone is still debatable. In aWorld Journal of Surgical Oncology 2007, 5:10 http://www.wjso.com/content/5/1/10
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recent randomized clinical trial comparing blue dye alone
with combined dye and isotope technique for sentinel
lymph node biopsy in breast cancer, combined mapping
was superior to blue dye alone in identification of the sen-
tinel node(s), but accuracy and false-negative rates were
similar [11]. Other reports suggest that with the increasing
success of isotope mapping, the marginal benefit of blue
dye utilization (when the sentinel lymph node is identi-
fied by blue dye alone) is small and declines further with
experience (from 9% – 3%) [12], making the application
of radio-colloid only, the preferred method for SLNB [13].
Hand-held gamma probes are nowadays smaller and
more manoeuvrable, with better shielding for directional
detection of gamma rays, making the method even more
applicable. Furthermore, the reported high identification
rates of the sentinel lymph node(s) with the use of radio-
colloid only, make the isotope radio guided method very
sensitive and extremely successful, avoiding all possible
blue dye anaphylactic reactions in allergic patients.
Relative contraindications
Previous breast surgery may disrupt the lymphatics from
the tumor site to the axilla and this may lead to higher
false negative results or failed procedures [14]. This seems
to be true for extensive breast surgery such as reduction
mammoplasty or quadradenctomy but not for more con-
servative surgery or biopsy procedures.
Prior biopsy
Biopsy methods of a suspicious breast lump include fine
needle aspiration cytology, core or true cut biopsy, vac-
uum assisted stereotactic biopsy and even more invasive
procedures such as incisional or excisional biopsy. Many
of the important prospective, large-series, reports on SLNB
excluded patients with previous excisional biopsy [15-17]
and/or previous axillary surgery [18], making the true
impact of prior breast biopsy rather uncertain. Some stud-
ies have suggested that SLNB for breast cancer may be less
accurate after excisional biopsy of the primary tumor
compared with core needle biopsy or fine-needle aspira-
tion biopsy. The main concern is that large-volume exci-
sional biopsy results in subsequent disruption of breast
lymphatics, decreasing the likelihood of successful lym-
phatic mapping. Therefore, any nodes removed after an
excisional biopsy may not actually be an accurate reflec-
tion of lymphatic drainage from the site of the primary
tumor. High failed sentinel lymph node identification
rates (up to a 7-fold increase) after excisional biopsy and
a significantly higher lymphatic mapping failure rate was
reported by certain authors [18,19]. Feldman et al. [14], in
their study suggested that false-negative results in SLNB
were increased only in patients who had prior excisional
biopsies, but also reported increased accuracy for the pro-
cedure once the protocols were altered with increased
number and volume of injections. In all three studies,
only radioactive colloid was used for lymphatic mapping
via peritumoral injection.
However, ample up to date data, suggests that prior breast
biopsy, including excisional biopsy, does not affect the
success or the accuracy of the procedure [20-24]. Haigh et
al., [20] reported that SLNB was highly successful in breast
cancer patients regardless of biopsy method (stereotactic
core biopsy, fine-needle aspiration, or excisional biopsy),
excision volume, and the interval between the biopsy and
the SLNB procedure. In addition, Miner et al., [25] also
demonstrated that SLNB is comparably successful regard-
less the extent of the prior biopsy. The University of Lou-
isville Breast Cancer Sentinel Lymph Node Study, in a
prospective multi-institutional study reported that exci-
sional biopsy does not significantly affect the accuracy of
the SLNB, nor does changes the type of definitive surgical
procedure [26]. Data from the European Institute of
Oncology is in accordance, suggesting that SLNB accuracy
after a previous breast biopsy is comparable with the
results obtained in validation studies [24]. False negative
results [22,23] and regional recurrence rates [24] seem to
be similar after fine needle aspiration or excisional biopsy
as other multi-institutional studies confirm. Results from
the John Wayne Cancer Institute, demonstrated that SLNB
was accurate and successful regardless of the biopsy proce-
dure previously performed or the volume of the tissue
removed [20]. Furthermore, it was shown that the size of
the tumor, interval from prior biopsy and the tumor loca-
tion did not significantly alter the procedure, with false
negative rates for the entire series of 3,2%. Therefore, it
seems that any type of previous breast biopsy (including
excisional biopsy) does not affect the accuracy or success
rate of SLNB [2,27-29]. It is however, warranted that injec-
tion of radio colloid or dye directly into the biopsy cavity
should be avoided since it may cause spillage and inaccu-
rate lymphatic mapping.
Lymphoscintigraphy (LS) is often a very useful tool to
combine with SLNB, especially in patients who have
already undergone excisional biopsy. Recent reports sug-
gest that the sensitivity and visualization rates for lympho-
scintigraphy seem to be unaffected by prior excisional
biopsy [21]. In two prospective studies using completion
axillary dissection, the accuracy, sensitivity and predictive
value of intraoperative lymphatic mapping and the SLNB
was unchanged regardless of previous excisional biopsy,
when a sentinel node was visualized on the preoperative
lymphoscintigram [20,30]. Lymphoscintigraphy in SLNB
can provide an accurate map of the pattern of lymphatic
drainage from the primary tumor site and successfully
identify the sentinel node(s). This is very important in
cases of non-axillary drainage of the tumor or disrupted
lymphatics. The implications of such drainage to unpre-
dicted lymph nodes are indeed profound. In such casesWorld Journal of Surgical Oncology 2007, 5:10 http://www.wjso.com/content/5/1/10
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the sentinel node(s) may be found in other, less frequent,
sites that include the internal mammary chain, the subcla-
vicular area, the contralateral axillary basin, the interpec-
toral lymph nodes or the breast parenchyma. Therefore,
imaging is essential for preoperative localization of possi-
ble non-axillary sentinel lymph node(s). Lymphoscintig-
raphy with direct visualization of the sentinel node(s)
may reduce the failure rate of SLNB and even lower the
small, but significant, percentage of false negative rates
that result from the existence of alternative (non-axillary)
lymphatic drainage pathways [31]. Visualization rates for
LS are reported between 76%-95% using 99mTc-labeled
small particle radio-colloids and high-resolution collima-
tors. Non-visualization of the lymphatic pathways and/or
sentinel node(s) may be due to either technical errors,
such as inadequate utilization of radio-colloid, improper
injection site and inappropriate timing, or to true lym-
phatic blocking from cancer cells. Moreover, an exten-
sively damaged lymphatic network from previous surgery
may impede radiopharmaceutical migration, causing non
visualization of the tumour's sentinel node(s). The use of
a sufficient amount of radioactivity (at least 100 MBq) is
recommended for lymphatic mapping in breast cancer,
especially in obese and/or elderly women. It has been
shown that delayed imaging and re-injection of the radio-
active tracer can increase the visualisation rate. In a multi-
variate regression analysis [32], scintigraphic non-
visualisation was independently associated with increased
patient age, decreased tracer dose and increased number
of tumour-positive lymph nodes. Other reports seem to
concur that patients with tumor positive nodes have
increased risk of LS failure and report failure rates of up to
50% when more than four nodes are involved with meta-
static disease. However, non-visualised sentinel node(s)
during lymphoscintigraphy can be identified intraopera-
tive in more than half of the patients, using a hand held
gamma probe and/or blue dye. In the rest patients, palpa-
tion of the axilla during surgery and axillary node sam-
pling seems to be a safe alternative. For this reasons non
visualization of the sentinel node during LS should not be
considered a contraindication to SLNB. Furthermore, cer-
tain authors suggest that lymphoscintigraphy findings do
not enhance the success of intraoperative identification of
the sentinel node nor alter the postoperative management
of patients with early stage breast cancer and thus, should
not be considered a routine procedure [33].
Previous breast and axillary surgery
An increasing proportion of patients with breast cancer
choose to undergo breast conserving therapy (BCT) and
10–15% of them will develop local or regional recurrent
disease within 10 years of follow-up [34,35]. Similarly,
the same proportion of local relapses is seen in patients
with ductal carcinoma in situ (DCIS) treated with BCT
and radiotherapy [36,37]. This is the main reason why the
already proven efficacy of the SLNB in primary breast dis-
ease has led to a new interest for the procedure in the re-
operative setting. Although previous breast surgery was
considered a contra-indication for SLNB, today this
notion is being re-evaluated. The minimum requirement
for a successful SLNB is the presence of a patent lymphatic
pathway between the tumor (either primary or recurrent)
and the sentinel node(s). Disrupted lymphatics may as
well be reformed soon after the initial operation or be re-
diverted in a different lymphatic route and an unob-
structed lymphatic system is assumed if no postoperative
lymphedema is present. According to many authors
[1,2,27-29], any kind of biopsy for breast cancer as well as
non extensive breast surgery, is not a contraindication to
SLNB and does not vitiate its success. However, more rad-
ical breast surgery such as reduction mammoplasty, aug-
mentation mammoplasty through an axillary incision
and quadradenctomy may be related to higher false nega-
tive rates and inability to locate the sentinel node(s).
Again, the most important anatomic consideration in
mind is an intact lymphatic system and thus, if the tumor
is located in an intact quadrant of the breast, even a recent
reduction procedure is unlikely to affect the efficacy of the
SLNB [1]. Currently there are no data to discourage the
use of SLNB in breast cancer patients who undergo imme-
diate reconstruction or who previously had augmentation
or reduction mammoplasty [38,39]. Lymphatics from the
lateral and upper quadrants of the breast to the axilla are
usually not damaged after breast reduction surgery or cos-
metic breast implants in the sub-mammary or sub-pecto-
ral position, especially if the surgery was performed more
than 6–12 months previously [2]. More studies are
needed to elucidate this matter, but if the SLNB is per-
formed in these settings, it may be safer to be combined
with preoperative lymphoscintigraphy to evaluate lym-
phatic routing.
Similarly, SLNB after axillary surgery has not been widely
evaluated and most reports exclude patients with prior
axillary dissection. However, few published studies report
that prior axillary dissection seems to make the procedure
less accurate. Port et al., reported that repeat SLNB failed
in 25% of patients compared with less than 5% among
women who had not previous axillary surgery [40]. On
the other hand, a study from the Memorial Sloan Ketter-
ing Cancer Centre showed that re-operative SLNB after
previous axillary lymph node dissection (ALND) is feasi-
ble in selected breast cancer patients and is more likely to
succeed when fewer that 10 nodes were removed during
the earlier procedure [41]. In this study, the identification
rate for the SLNB in patients with primary breast carci-
noma was between 94% and 97% with a false negative
rate of 4–5%. In the re-operative setting identification rate
fall to 87% in patents with 10 or less axillary lymph nodes
previously removed and to 44% if more than 10 nodesWorld Journal of Surgical Oncology 2007, 5:10 http://www.wjso.com/content/5/1/10
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were previously excised. With increasing number of nodes
previously removed, re-operative SLNB was less success-
ful. Recent data from the European Institute of Oncology
is in accordance with these findings and suggests that
SLNB after a previous breast or axillary operation is tech-
nically feasible and effective, but in selected breast cancer
patients with local recurrence [41]. For the 10–15% of
breast cancer patients who develop local or regional
relapse, SLNB has exhilarating potential, but a larger
patient population and a longer follow-up are necessary
to confirm these exciting preliminary multi-institutional
findings. False negative rates after prior axillary dissection
are very difficult to determine and require long term fol-
low-up, since a previous axillary lymph node dissection
removing the majority of axillary nodes will leave only the
sentinel node(s) remaining and so a back-up axillary
clearance is impossible to perform.
Advanced disease and neoadjuvant chemotherapy
Most patients with locally advanced breast cancer have
large tumors and a high incidence of axillary node
involvement, for which they may be offered neoadjuvant
chemotherapy. However, a significant proportion of these
patients (40%-48%) will not harbour metastatic disease
in the axilla and thus may be spared an unnecessary
ALND. Neoadjuvant chemotherapy (NC) was initially
used to down-stage what is considered inoperable disease.
Under those circumstances, tumor response implied also
response in regional or even distant metastases [42]. In
addition, neoadjuvant chemotherapy has been applied
with success in locally advance disease. Recently, NC is
being offered to patients with smaller tumors (stage II dis-
ease, with tumors larger than 3 cm), since trials have dem-
onstrated that breast conservation treatment following
neoadjuvant radiotherapy is as safe in terms of local-
regional control and overall survival, as mastectomy
[43,44]. SLNB has been used so far, to a very limited
degree, in selected breast cancer patients with locally
advanced degree receiving neoadjuvant chemotherapy
and many authors consider that it should not be per-
formed outside a clinical trial [1]. The success rate of the
procedure may be lower and false negative rates higher
due to histological changes in the breast and the draining
lymphatics caused by the chemotherapeutic agents [45],
and in the possible regression of the disease in the sentinel
node(s) but not elsewhere in the axilla. It has been sug-
gested that, alterations in the anatomy of the lymphatics
draining the tumor could interfere with the lymphotropic
agents and prevent their unobstructed transit to the senti-
nel node(s). However, if this was true, a difference in the
site and number of sentinel nodes might be expected as
well as altered absorption of radio-colloid agent resulting
in either higher or lower sentinel node radioactivity
counts. Recent studies have failed to prove this theory,
finding no differences in the number, location or radioac-
tivity status of the sentinel node(s) in patients receiving
neoadjuvant therapy [46]. Lymphatic mapping has dem-
onstrated that lymphatics in the breast are regional and
not point specific, covering wide areas of the breast and
this conclusion further rationalizes the practice of the
SLNB. Moreover, recent data suggest a role for SLNB in the
subgroup of patients treated with neoadjuvant chemo-
therapy and clinically or ultrasound negative axillary
nodes (N0) at the end of the treatment. Response rates to
neoadjuvant chemotherapy range from 65% to 90% [47],
and the majority of patients do achieve significant regres-
sion of both the primary tumor and the axilla metastases.
Therefore, it is reasonable to re-evaluate the role of the
SLNB in this patient subgroup. In the largest report to
date, updates data from the NSABP B-27 prospective ran-
domized trial evaluating the efficacy of preoperative ver-
sus postoperative docetaxel following preoperative
doxorubicin/cyclophosamide chemotherapy [48], an
identification rate for the sentinel node of 85% and false
negative rates of 12% were reported. Data from smaller
studies are in agreement, reporting identification rates
between 85% and 94% [49,50] and false negative rates of
as low as 0% to as high as an unacceptable 33% [51-56].
It seems that these preliminary reports suggest a potent
role for SLNB in locally advanced cancer and patients
receiving induction chemotherapy (except in inflamma-
tory cancer), but clearly, more trials including large
number of patients need to clarify the efficacy of SLNB in
the neoadjuvant setting. Moreover, there is no current
data on the long-run regional recurrence rate in these
patients, and since neoadjuvant treatment may eradicate
metastatic foci in the axillary lymph nodes, the long term
clinical and prognostic significance of negative findings
after the SLNB is not clear yet.
Tumour size
It is well documented that the incidence of axillary
tumour metastasis increases in respect with tumour size
[57]. Few years ago when the SLNB was first introduced,
the majority of surgeons reserved the procedure for breast
cancer patients with tumor size less than 2 cm. Even
today, the accuracy of SLNB had not been verified in larger
cancers, but it is becoming apparent that SLNB is techni-
cally feasible and highly accurate even in larger (T2 and
T3) tumors. About 30% of patients with breast tumors
larger than 4 cm have no axillary lymph mode metastasis
and therefore do not benefit from ALND. In a small pro-
spective study of SLNB followed by complete ALND for
breast cancers larger than 4 cm, both the identification
rate and the sensitivity of the procedure was equivalent to
those patients with smaller tumors [58]. Several other
studies concur, indicating no significant difference in
both the identification and false-negative rate in T3 versus
T1 tumors [59-62]. Therefore tumor size should not pre-
clude the use of the SLNB in those patients otherwise can-World Journal of Surgical Oncology 2007, 5:10 http://www.wjso.com/content/5/1/10
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didates for the procedure. Axillary lymph node dissection
can be avoided in nearly one third of patients with larger
tumours by focused examination of the sentinel lymph
node. However, the axilla must be always thoroughly pal-
pated during the SLNB procedure and any suspicious
lymph nodes should be removed.
Multicentric and multifocal disease
The incidence of multicentric (MC) and multifocal (MF)
disease in breast cancer ranges between 13% and 65%
[63]. By definition, the term multicentric disease describes
two or more carcinomas arising in separate quadrants of
the breast, or tumors more than 2–5 cm apart [64]. The
term multifocal disease refers to the presence of separate
foci of carcinoma in the same quadrant of the breast. The
presence of MC or MF in invasive breast cancer was con-
sidered a relative contraindication for the SLNB, since
there are suspicions that the multiple tumors might
involve more than one dominant lymphatic trunk drain-
ing to the regional axillary lymph nodes. Multiple lym-
phatic trunks might drain to different sentinel lymph
node(s) and may be overlooked. However, with the use of
lymphatic mapping and the increased experience in SLNB,
there is now increasing evidence-based support of the the-
ory that the lymphatics of the mammary gland drain
through a few common afferent lymphatic trunks to spe-
cific axillary sentinel lymph nodes, regardless of the
tumor location [65,66]. Evidence obtained the past few
years about the functional anatomy of the lymphatic
drainage of the breast supports the theory that all quad-
rants of the breast drain into same lymph node(s) [67,68].
In addition, there is a deep and a superficial lymphatic
system with a subareolar plexus that drains the axillary
lymph nodes via one or two main lymphatic vessels [69].
According to the Proceedings of the Consensus Confer-
ence on the Role of Sentinel Lymph Node Biopsy in Car-
cinoma of the Breast (2001), SLNB is not recommended
for women with multicentric disease outside the setting of
research protocols. On the other hand, the panel con-
cluded that multifocal disease is not a contraindication
for the procedure, when the tumors diameter is less than
3 – 5 cm [1]. The American Society of Clinical Oncology
Guidelines Recommendations for Sentinel Lymph Node
Biopsy (2005), considers the procedure acceptable for
MC-MF breast cancer, but notes that evidence is limited to
small scale trials [2]. A recent multi-institutional trial pre-
sented at the 55th Annual Cancer Symposium of the Soci-
ety of Surgical Oncology, reported no significant
differences in the identification rate and false negative
rates between patients with MC and MF disease in com-
parison with single site breast cancer patients [70], and
since then a few other studies have validated these find-
ings [71,72]. Several small non-randomized studies also
reported that the accuracy and efficacy of SLNB by subar-
eolar or intradermal injection of tracers was similar to that
of women with unifocal disease [71,73-75]. Reported
identification rates in MC and MF range from 90%-97%
[70,76] and false negative rates from 0% to 8% [71]. In
their series, with detection rate of 97% and false-negative
rate of 8%, the group at the Memorial Sloan-Kettering
Cancer Centre concluded that the accuracy of SLNB was
comparable to unicentric lesions and the Little Rock
group concurred [75]. Studies with larger patient popula-
tions and long term follow-up are necessary to prove the
efficacy of SLNB in the MC-MF setting, but preliminary
results suggest that the procedure may be an accurate alter-
native to ALND in patients with clinically negative axilla
and multicentral or multifocal breast cancer [76].
Ductal Carcinoma in-Situ
Ductal carcinoma in-situ (DCIS) has become nowadays a
common finding in patients with screen detected breast
cancer and represents approximately 20% of all breast
malignancies. By definition DCIS has no metastatic
potential while in the in situ phase, however extensive
DCIS may harbour invasive component that can poten-
tially spread to the axillary lymph nodes. This invasive
pattern may be missed in up to 5% to 20% of patients
undergoing core biopsy, because it may represent only a
small proportion of the overall tumor [77]. Although
node metastasis in patients with true DCIS are very
uncommon (0%-3%), sentinel node metastasis have been
detected in 13%-20% of extensive tumors with high
nuclear grade or areas of necrosis [78,79]. Other high risk
features of DCIS include a palpable or mammographic
mass with pluricentric microcalcifications, comedo type,
multicentric disease. and usually those patients are treated
by mastectomy. A very extensive and careful histological
examination of the tumour in DCIS is compulsory to
exclude any micro-invasive foci. Handling of the SLNB
specimen by the pathologist is crucial and detailed defini-
tions of metastasis have become important, especially
since immunohistochemistry techniques have been used
used [80]. The use of immunohistochemistry (IHC) to
detect keratin proteins will reveal metastatic breast carci-
noma in about 18% of axillary or sentinel lymph nodes
that appear negative on routine stains [81]. To date evi-
dence suggests a significantly poorer prognosis in patients
with such occult metastases, although data from large pro-
spective studies are lacking. The term "micro-metastasis"
refers to a cohesive cluster of malignant cells larger than
0.2 mm but smaller than 2 mm in diameter. "Submicro-
scopic metastases" best describes small cell clusters or
individual tumor cells less than 0.2 mm in diameter
found by immunohistochemistry techniques. The need
for completion axillary node dissection in these cases is
still controversial. For years there has been speculation
that micrometastases in axillary lymph nodes were clini-
cally insignificant [82], however most of the recent studies
have found a significantly poorer prognosis associatedWorld Journal of Surgical Oncology 2007, 5:10 http://www.wjso.com/content/5/1/10
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with micrometastases, suggesting that even such small
metastases cannot be safely overlooked [81,83]. Some
authors believe that micrometastases should be treated
with completion ALND or with adjuvant radiation ther-
apy [83-85]. On the other hand, no current evidence exist
that submicroscopic metastases or individual tumors cells
found within the sentinel lymph have an important prog-
nostic significance [86], and therefore require no further
treatment [83,87].
In conclusion, it seems that for patients with high risk
DCIS for invasive component, SLNB is justified and there-
fore recommended as an efficient procedure to evaluate
the status of the axilla [1,88,89]. On the other hand, in
patients with low risk DCIS (such as true non-comedo
DCIS) that is completely excised by surgery and with free
margins of resection, SLNB should be avoided since not
only it is unnecessary (due to the low possibility of meta-
static involvement), but could also jeopardize a successive
re-SLNB in case of invasive recurrence [90].
Age and body mass index
Increased age and body mass index (BMI) have been
linked to an increase incidence of SLNB failure [91,92].
This could have serious implications since a large propor-
tion of patients with breast cancer are senior and/or over-
weight. Sentinel lymph node biopsy seems to be feasible
regardless of the age of the patient but the identification
rate of the procedure may be impacted by increasing age
and BMI. Some authors speculate that anatomical changes
in the breast of elderly and obese patients, with decrease
in the density of the gland and increase of fatty tissue
deposit, may result in decreased lymphatic flow and
increased SLNB failure rates. Furthermore, the high con-
tent of subcutaneous and axillary adipose tissue makes
palpation harder and the identification of the sentinel
node more difficult, especially when only blue dye is uti-
lized. Three multi-institutional studies found that the sen-
tinel node was found less frequently in women older than
50 years of age [18,22,23], with reported identification
rates of 87.6% versus 92.6% for younger patients [22],
while other trials report a strong inverse relationship
between increased BMI (>30) and identification rate for
the SLNB [93]. The identification rate was 99% for
patients with BMI < 20, 96.6% for BMI of 30 and 94.2%
for BMI of 40. However, in all cases acceptable identifica-
tion and false negative rates where achieved when the pro-
cedure was performed with use of both blue dye and
radio-colloid. Dual-agent injection technique makes the
procedure technical feasible and efficient in senior and/or
overweight breast cancer patients and it seems that SLNB
is a suitable and accurate alternative to routine axillary
dissection for this particular patient population. However,
surgeons performing the procedure should be aware that
the radioactive counts might not be greater than 20 or 30
per node, and once again the surgical clinical judgment
should guide all intraoperative decision making.
Pregnancy
Breast cancer is the most common malignancy associated
with pregnancy, with an incidence of 1 in 10,000 to 1 in
3,000. It is speculated that with the increase in delayed
childbearing age, breast carcinoma diagnosed during
pregnancy may become more frequent [94,95]. The role
of SLNB in pregnant women with breast cancer is not
clear. The radioactivity from the procedure might harm
the foetus, plus the breast lymphatic pathways may be
altered in pregnancy. Many authors suggest that since the
risk of lymphatic mapping by blue dye and/or radiocol-
loid are still unknown, it is advised not to perform SLNB
in pregnant women until more data is available [1,2]. The
agents used for the identification of the sentinel node are
blue dye and radio-colloid technetium. The blue dye
might be blue de methylene, lymphazurin, isosulfan blue
and patent blue. Blue dyes such as lymphazurine (a class
C drug) have not been tested in pregnant animals or
humans and thus should not be utilized in the pregnant
or lactating patient. Radio-colloids include technetium
sulphur colloid and technetium labelled albumin, which
are considered safer agents. Recent data suggests that the
radiation dose to the foetus is minimal, allowing reason-
able consideration for the SLNB during pregnancy [2,96].
The amount of radioactivity utilized in SLNB is very low
compared to standard radionuclide procedures. The radi-
oactivity dose ranges from 250 μCi (1/40 of the bone scan
dose) to 2 mCi and most of the injected radiocolloid stays
at the injection site or moves to the sentinel node(s), both
of which are excised during the procedure. Therefore,
minute only amounts of radioactive colloid might reach
the foetus with harmless effects. The total radiation expo-
sure of the patient undergoing SLNB using 0.5 mCi of
radiolabeled colloid is about the same as from a four
exposure mammogram, at 0.4 mSv (1]. Recent studies
claim that foetal exposure to radiation using radio-colloid
agents such as technetium-99 m for lymphoscintigraphy
and localization of the sentinel node is low and should
not be considered a contraindication [97]. It might be so
that the greater risk to the foetus is from the general anaes-
thesia, since foetal radiation doses are negligible and well
below levels associated with risk concerns. Pandit-Taskar
et al. [98], reported that the maximum estimated foetal
exposure (with the worst case conservative assumptions)
may be less than 3% of the Nuclear Regulatory Commis-
sion (NRC) monthly guidline of 0.5 mSv, and less than
0,3% of the NRC occupational exposure limits during ges-
tation period, of 5 mSv. They suggest that lymphoscintig-
raphy and SLNB can be safely applied during pregnancy,
as estimated radiation doses are not associated with sig-
nificantly increased risk to the foetus. However, more
experimental trials need to be performed to clear this issueWorld Journal of Surgical Oncology 2007, 5:10 http://www.wjso.com/content/5/1/10
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and until that time, SLNB should not be offered to preg-
nant women under 30 weeks gestation, since this is the
critical period for foetal organogenesis. Furthermore,
since small quantities of the radioactive colloid can be
excreted in breast milk, lactation should be avoided for a
few days after the SLNB procedure.
Radiation protection issues
The use of Technetium-99 m labeled colloids for lympho-
scintigraphy and radio-guided surgery does not entail
dangerous radiation burden to patients undergoing SLNB
[99,100]. Furthermore, radioactivity levels to personnel
handling contaminated materials is also negligible, since
very low doses of radio-colloid are utilized during SLNB
and at least 2 to 3 physical half lives elapse between tracer
injection and the completion of the surgical procedure
[101]. The cumulative doses involved in the procedure
correspond at most to about 1% (mean absorbed dose) or
about 10% (mean effective dose) of the annual dose lim-
its for the general population. Radiation safety badges are
not considered necessary for surgeons, nurses and pathol-
ogists. Radioactivity contamination in operating room
materials is also minimal and does not require any special
handling procedure. Letting radioactivity decay with time
by storing the specimens for a few hours, is a sufficient
precaution for pathologists handling the SLNB specimens.
Special considerations for the waste radioactive materials
are not required, but it is suggested that such waste mate-
rials are sealed and stored for decay at the nuclear depart-
ment before disposal. If stored for 60 hours, which
correlates to 10 technetium-99 m lives, the radioactive
content of the waste falls 1000-fold. Transportation and
disposal of decayed radioactive waste should proceed fur-
ther according to local regulatory requirements.
Surgeons experience and learning curve
SLNB is a multi-disciplinary effort involving surgical
oncology, nuclear medicine and pathology. Each member
of the team must rely on each other's contribution for the
accurate and efficient performance of the procedure. It has
been reported to exist a close correlation between the
number of procedures performed by the team and the
positive predictive value of the technique, with values
ranging from 71% for experience of less than 40 proce-
dures to 98% after more than 100 procedures [18,23]. The
learning curve is considered to be completed after per-
forming more than 50–60 procedures [102], and a success
rate of more than 94% should be achieved. Full axillary
lymph node dissection should be performed on all
patients during the learning phase, irrespective of SLNB
histology.
Discussion
In breast cancer, hematogenous spread of tumor cells may
precede or be coincident with lymphatic spread and so far
regional lymphadenectomy has proven beneficial in
terms of staging and loco-regional control of the disease,
but has failed to produce an overall survival benefit. Fur-
thermore, since about 70%-80% of ALND in breast cancer
patients will reveal no metastatic disease, the benefits
from regional lymphadenectomy, when compared with
morbidity and cost, may be small. Sentinel lymph node
biopsy is an alternative procedure to ALND which pro-
vides accurate information on the status of the regional
lymphatics and converts elective or prophylactic axillary
node dissection into beneficial therapeutic dissection
[103]. Subsequently, only the breast cancer patients who
truly profit from ALND will risk the high morbidity of this
procedure and a great proportion of node negative
patients will be spared an unnecessary operation. There
are two important considerations that must be taken into
account when certifying a multidisciplinary team for
SLNB. First of all, the sentinel lymph node must be suc-
cessfully identified in more than 95% of patients (failure
rate < 5%) and secondly, the negative rate of the proce-
dure should be less that 3–5%. Also, the fraction of
patients with positive sentinel lymph node(s) should be
20%-30% in patients with T1a-b breast cancer and about
35% in patients with T1a-c cancer [101]. Higher rates are
expected for larger tumors and more advanced disease.
False negative results always harbor a risk for the patient
undergoing SLNB. However, prevalence of clinically overt
axillary metastases is less than 1% after a median follow-
up of up to 57 months [16,104-106]. Currently there are
randomized trials being conducted on the efficiency and
efficacy of the SLNB that will provide answers to vital,
unresolved issues such as the possible differences in sur-
vival and local-regional recurrence between standard axil-
lary lymph node dissection and the SLNB.
Conclusion
Like all surgical procedures, the sentinel node biopsy is
not appropriate for each and every patient. Certain condi-
tions involving not only host factors, but also tumor bio-
logic characteristics may have a negative impact on the
success rate of the procedure. However, the overall frac-
tion of patients unsuitable or with many risk factors com-
promising the success of the SLNB is very small.
Nevertheless, these patients need to be successfully identi-
fied, appropriately advised and cautioned, and so do the
surgeons that perform SLNB. In conclusion, when per-
formed by an experienced multi-disciplinary team, senti-
nel lymph node biopsy is a highly effective and accurate
alternative to standard level I and II axillary clearance in
the vast majority of patients with early breast cancer.
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